Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 4-Nitrocatechol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | ERN1 | O75460 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA5A | P35218 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Nitrocatechol SCHEMBL2977452 | 1.00 | GPR35 (0.60) | GPR35ALDH1A1TSHRTP53HPGD | |
| 4-Nitrocatechol SCHEMBL156909 | 0.92 | TSHR (0.69) | GPR35ALDH1A1TSHRTP53HPGD | |
| 4-Nitrocatechol SCHEMBL1608536 | 0.92 | TSHR (0.69) | GPR35ALDH1A1TSHRTP53HPGD | |
| 4-Nitrocatechol SCHEMBL11765698 | 0.92 | TSHR (0.69) | GPR35ALDH1A1TSHRTP53HPGD | |
| 4-Nitrocatechol SCHEMBL30262908 | 0.90 | GPR35 (0.58) | GPR35ALDH1A1TSHRTP53HPGD | |
| 4-Nitrocatechol SCHEMBL28290085 | 0.90 | ALDH1A1 (0.67) | GPR35ALDH1A1TSHRTP53HPGD | |
| 4-Nitrocatechol SCHEMBL4071135 | 0.90 | ALDH1A1 (0.67) | GPR35ALDH1A1TSHRTP53HPGD | |
| Sulfuric Acid SCHEMBL1881177 | 0.85 | GAA (0.65) | GPR35ALDH1A1TSHRTP53HPGD | |
| 4-Nitrocatechol SCHEMBL28778474 | 0.84 | ALDH1A1 (0.60) | GPR35ALDH1A1TSHRTP53HPGD | |
| 2-Amino-4-Nitrophenol SCHEMBL3337658 | 0.83 | GAA (0.86) | GPR35ALDH1A1TSHRTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376712-A1 | PAPER-BASED ANALYTICAL DEVICE FOR POTENTIOMETRIC ENZYME DETECTION | ABD RABBOH HISHAM S M (SA) | 2025-12-11 | — | — | US | claimed |
| US-20240093166-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-21 | — | — | US | claimed |
| US-20240076634-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-07 | — | — | US | claimed |
| US-20240002819-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-01-04 | — | — | US | claimed |
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | GINKGO BIOWORKS, INC. | 2023-10-26 | — | — | US | claimed |
| US-11773382-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-10-03 | — | — | US | claimed |
| US-11767518-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-09-26 | — | — | US | claimed |
| US-11708567-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-07-25 | — | — | US | claimed |
| US-11708593-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-07-25 | — | — | US | claimed |
| US-20230151339-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2023-05-18 | — | — | US | claimed |
| US-20220010344-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | GINKGO BIOWORKS, INC. | 2022-01-13 | — | — | US | claimed |
| US-20210363503-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | OPTIMVIA LLC (US) | 2021-11-25 | — | — | US | claimed |
| US-20210363504-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2021-11-25 | — | — | US | claimed |
| US-20210363505-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2021-11-25 | — | — | US | claimed |
| EP-3911737-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | Optimvia, LLC (US) | 2021-11-24 | — | — | EP | claimed |
| CN-113646427-A | Engineered arylsulfate-dependent enzymes | 奥普蒂姆维亚有限公司 | 2021-11-12 | — | — | CN | claimed |
| WO-2021007429-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | OPTIMVIA LLC (US) | 2021-01-14 | — | — | WO | claimed |
| WO-2020150350-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | OPTIMVIA, LLC (US) | 2020-07-23 | — | — | WO | claimed |
| EP-2137204-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | Amicus Therapeutics, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008128089-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | AMICUS THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220010344-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | CSGALNACT1, NANS, STS | GPR35 2770/4885ALDH1A1 1281/4885TSHR 2026/4885 |
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | CSGALNACT1, NANS, STS | GPR35 2881/4885ALDH1A1 1300/4885TSHR 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.